stoxline Quote Chart Rank Option Currency Glossary
  
Acelyrin, Inc. (SLRN)
8.45  0.29 (3.55%)    02-27 14:40
Open: 8.31
High: 8.49
Volume: 527,134
  
Pre. Close: 8.16
Low: 8.1
Market Cap: 823(M)
Technical analysis
2024-02-27 2:17:13 PM
Short term     
Mid term     
Targets 6-month :  10.18 1-year :  11.89
Resists First :  8.71 Second :  10.18
Pivot price 7.84
Supports First :  7.37 Second :  6.55
MAs MA(5) :  7.83 MA(20) :  7.85
MA(100) :  8.09 MA(250) :  0
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  50.4 D(3) :  30.7
RSI RSI(14): 60.3
52-week High :  29.87 Low :  5.69
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ SLRN ] has closed below upper band by 0.4%. Bollinger Bands are 38% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.46 - 8.51 8.51 - 8.55
Low: 7.33 - 7.38 7.38 - 7.43
Close: 8.07 - 8.16 8.16 - 8.24
Company Description

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.

Headline News

Mon, 26 Feb 2024
Acelyrin (NASDAQ:SLRN) Trading Up 11.3% - MarketBeat

Mon, 26 Feb 2024
Eagle Asset Management Inc. Sells 161687 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat

Fri, 23 Feb 2024
Rafferty Asset Management LLC Makes New Investment in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat

Wed, 21 Feb 2024
Acelyrin, Inc. (NASDAQ:SLRN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Tue, 16 Jan 2024
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Acelyrin, Inc. of a Class Action Lawsuit and a ... - PR Newswire

Tue, 16 Jan 2024
SHAREHOLDER ALERT: Potential Recovery for Acelyrin, Inc. (SLRN) Investors Affected by Stock Drop - Levi & ... - Barron's

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 97 (M)
Shares Float 64 (M)
Held by Insiders 20.6 (%)
Held by Institutions 90.8 (%)
Shares Short 6,450 (K)
Shares Short P.Month 6,770 (K)
Stock Financials
EPS -5.06
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.53
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -114 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -1.68
PEG Ratio 0
Price to Book value 1.12
Price to Sales 0
Price to Cash Flow -7.22
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android